Ga Yoon Ku, Beom-Jin Kim, Ji Won Park, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
{"title":"Single-Dose Versus Multiple-Dose Prophylactic Antibiotics in Minimally Invasive Colorectal Surgery: A Propensity Score Matched Analysis.","authors":"Ga Yoon Ku, Beom-Jin Kim, Ji Won Park, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park","doi":"10.3346/jkms.2024.39.e305","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent guidelines about preventing surgical site infections (SSIs) recommend against the administration of prophylactic antibiotics after surgery. However, many colorectal surgeons still prefer prolonged use of prophylactic antibiotics. While minimally invasive surgery (MIS) has become the standard for colorectal cancer surgery, there were few studies about proper dose of prophylactic antibiotics in minimally invasive colorectal surgery.</p><p><strong>Methods: </strong>This is a retrospective study. All patients underwent elective colorectal cancer surgery using MIS. Intravenous cefotetan was administered as a prophylactic antibiotic. Two groups were classified according to the dose of prophylactic antibiotics: a group using a single dose preoperatively (single-dose group) and a group using a preoperative single dose plus additional doses within 24 hours after surgery (multiple-dose group). The SSI rates between the two groups were compared before and after propensity score matching (PSM). Risk factors of SSIs were assessed using univariate and multivariable analysis.</p><p><strong>Results: </strong>There were 902 patients in the single-dose group and 330 patients in the multiple-dose group. After PSM, 320 patients were included in each group. There were no differences in baseline characteristics and surgical outcomes except the length of hospital stay. SSI rates were not different between the two groups before and after PSM (before 2.0% vs. 2.1%, <i>P</i> = 0.890; after 0.9% vs. 1.9%, <i>P</i> = 0.505). In multivariable analysis, American Society of Anesthesiologists class 3, rectal surgery, intraoperative transfusion, and larger tumor size were identified as independent factors associated with SSI incidence.</p><p><strong>Conclusion: </strong>A single preoperative dose of prophylactic antibiotics may be sufficient to prevent SSIs in elective MIS for colorectal cancer.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":"39 47","pages":"e305"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2024.39.e305","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Recent guidelines about preventing surgical site infections (SSIs) recommend against the administration of prophylactic antibiotics after surgery. However, many colorectal surgeons still prefer prolonged use of prophylactic antibiotics. While minimally invasive surgery (MIS) has become the standard for colorectal cancer surgery, there were few studies about proper dose of prophylactic antibiotics in minimally invasive colorectal surgery.
Methods: This is a retrospective study. All patients underwent elective colorectal cancer surgery using MIS. Intravenous cefotetan was administered as a prophylactic antibiotic. Two groups were classified according to the dose of prophylactic antibiotics: a group using a single dose preoperatively (single-dose group) and a group using a preoperative single dose plus additional doses within 24 hours after surgery (multiple-dose group). The SSI rates between the two groups were compared before and after propensity score matching (PSM). Risk factors of SSIs were assessed using univariate and multivariable analysis.
Results: There were 902 patients in the single-dose group and 330 patients in the multiple-dose group. After PSM, 320 patients were included in each group. There were no differences in baseline characteristics and surgical outcomes except the length of hospital stay. SSI rates were not different between the two groups before and after PSM (before 2.0% vs. 2.1%, P = 0.890; after 0.9% vs. 1.9%, P = 0.505). In multivariable analysis, American Society of Anesthesiologists class 3, rectal surgery, intraoperative transfusion, and larger tumor size were identified as independent factors associated with SSI incidence.
Conclusion: A single preoperative dose of prophylactic antibiotics may be sufficient to prevent SSIs in elective MIS for colorectal cancer.
背景:最近关于预防手术部位感染(ssi)的指南建议手术后不要使用预防性抗生素。然而,许多结直肠外科医生仍然倾向于长期使用预防性抗生素。虽然微创手术已成为结直肠癌手术的标准,但关于微创结直肠癌手术中预防性抗生素的适当剂量的研究却很少。方法:回顾性研究。所有患者均采用MIS进行择期结直肠癌手术。静脉注射头孢替坦作为预防性抗生素。根据预防性抗生素的剂量分为两组:术前单剂量组(单剂量组)和术前单剂量加术后24小时内加剂量组(多剂量组)。比较倾向评分匹配(PSM)前后两组的SSI发生率。采用单因素和多因素分析评估ssi的危险因素。结果:单剂量组902例,多剂量组330例。经PSM治疗后,每组320例。除了住院时间外,基线特征和手术结果没有差异。PSM前后两组SSI发生率无显著差异(术前2.0% vs. 2.1%, P = 0.890;0.9% vs. 1.9%, P = 0.505)。在多变量分析中,美国麻醉医师学会三级、直肠手术、术中输血和较大的肿瘤大小被确定为与SSI发生率相关的独立因素。结论:术前单剂量预防性抗生素可能足以预防结直肠癌选择性MIS患者的ssi。
期刊介绍:
The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.